HEOR Case Studies
Presenter and moderator disclosures
The following presenters have no financial relationships to disclose:
David B. Rein, PhD; Ecosse Lamoureux, PhD, MSc; Marilyn James, PhD
The following presenters and moderator disclosed financial relationships:
Melissa M. Brown, MD, MN, MBA: Center for Value-Based Medicine: (E, I);Thomas Arno Albini, MD: Adverum Biotechnologies: (C); Allergan: (C); Applied Genetic Technologies Corp: (C); Bausch+Lomb/Valeant Pharmaceuticals: (C); Beaver Visitec: (C); Mallinckrodt Pharmaceuticals: (C); Clearside Biomedical, Inc.: (C); Eyepoint Pharmaceuticals: (C); Genentech: (C); Novartis: (C); RegenexBio: (C)Andrew F. Smith, PhD, MSc: MedMetrics Inc.: (E) (Moderator)
The following presenters and moderator disclosed financial relationships:
Melissa M. Brown, MD, MN, MBA: Center for Value-Based Medicine: (E, I);Thomas Arno Albini, MD: Adverum Biotechnologies: (C); Allergan: (C); Applied Genetic Technologies Corp: (C); Bausch+Lomb/Valeant Pharmaceuticals: (C); Beaver Visitec: (C); Mallinckrodt Pharmaceuticals: (C); Clearside Biomedical, Inc.: (C); Eyepoint Pharmaceuticals: (C); Genentech: (C); Novartis: (C); RegenexBio: (C)Andrew F. Smith, PhD, MSc: MedMetrics Inc.: (E) (Moderator)
Description
Discover how investigators evaluated the economic burden of vision loss and blindness and non-infectious inflammatory eye disease (NIIED) in the United States. Learn the similarities and differences when assessing the health economics of diabetic retinopathy screening in Singapore versus in the United Kingdom and more.
Session agenda
- The economic burden of vision loss and blindness in the United States by David B. Rein, PhD
- Cost-utility analysis and ophthalmic interventions by Melissa M. Brown, MD, MN, MBA
- Cost-effectiveness of a national diabetic retinopathy screening program in Singapore by Ecosse Lamoureux, PhD, MSc
- The health economics of diabetic retinopathy screening in the United Kingdom: From opportunistic to systemic to a risk-based (personalized) approach by Marilyn James, PhD
- Non-infectious inflammatory eye disease (NIIED) in a commercially-insured population in the United States by Thomas Arno Albini, MD
